At high doses (>10 mcg/kg/min), what are the hemodynamic effects of dopamine?

At high doses (>10 mcg/kg/min), what are the hemodynamic effects of dopamine?

• A. >10 mcg/kg/min -> beta2-mediated vasodilation only
• B. >10 mcg/kg/min -> decreased SVR and increased renal blood flow
• C. >10 mcg/kg/min -> selective DA1 with renal vasodilation
• D. >10 mcg/kg/min -> alpha (plus B1, B2, DA1); increased SVR, PVR, and HR; decreased renal blood flow; increased afterload can decrease CO

Answer: (D)

Dopamine’s effects depend on the dose because it acts on different receptors as the dose changes. At high doses, alpha-adrenergic vasoconstriction becomes the dominant force, on top of the beta and dopaminergic actions that are still present. This means blood vessels constrict more overall, raising systemic vascular resistance and, with some contribution to the pulmonary circulation, increasing pulmonary vascular resistance as well. The beta-1 effect adds tachycardia and increased contractility, but the heightened afterload from the vasoconstriction can actually reduce forward flow, so cardiac output may fall or not rise as much as expected. The renal arteries also constrict, decreasing renal blood flow. So, the profile at high dose is increased SVR and PVR, higher heart rate, reduced renal perfusion, and potential decreased CO due to increased afterload. This differs from the low-to-intermediate dose ranges, where dopaminergic renal vasodilation and beta-1–mediated increases in heart rate and contractility predominate, and from patterns claiming selective DA1 effect or predominant beta-2–mediated vasodilation, which do not apply at high doses.

Dopamine’s effects depend on the dose because it acts on different receptors as the dose changes. At high doses, alpha-adrenergic vasoconstriction becomes the dominant force, on top of the beta and dopaminergic actions that are still present. This means blood vessels constrict more overall, raising systemic vascular resistance and, with some contribution to the pulmonary circulation, increasing pulmonary vascular resistance as well. The beta-1 effect adds tachycardia and increased contractility, but the heightened afterload from the vasoconstriction can actually reduce forward flow, so cardiac output may fall or not rise as much as expected. The renal arteries also constrict, decreasing renal blood flow. So, the profile at high dose is increased SVR and PVR, higher heart rate, reduced renal perfusion, and potential decreased CO due to increased afterload.

This differs from the low-to-intermediate dose ranges, where dopaminergic renal vasodilation and beta-1–mediated increases in heart rate and contractility predominate, and from patterns claiming selective DA1 effect or predominant beta-2–mediated vasodilation, which do not apply at high doses.